A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA2, germline, mutation, screening | 1 Comment »
While excellent outcomes of stereotactic body radiation therapy (SBRT) have been reported since it was first used to treat prostate cancer in 2003, the delivered doses have ranged from 35 Gy in five treatments to 40 Gy in five treatments. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, dose, optimal, radiation, SBRT, stereotactic | 6 Comments »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
An article just published in the journal Cancer states that — at least here in the USA — there was no significant increase in risk for suicide within the first year after diagnosis among men diagnosed with prostate cancer between 2000 and 2014 … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: cancer, Diagnosis, prostate, risk, suicide | 1 Comment »
Our regular readers will remember that we have commented on and off on the development of different types of system that (maybe) can be used to test for risk of cancer based on smell … an ability that has been clearly demonstrated among certain trained dogs and one of two electronic systems. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: breath, cancer, Diagnosis, risk, screening, smell | Leave a comment »
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Kattan, MRI. mpMRI, MSKCC, multiparametric, nomogram, Partin, prognosis, risk, score | 3 Comments »
